The MYG1 Knockout KYSE-150 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population in which the MYG1 gene has been disrupted to establish a loss-of-function model. Derived from the KYSE-150 esophageal squamous cell carcinoma line, this heterogeneous pool provides a genetically diverse system for studying MYG1-dependent phenotypes without clonal selection. The targeted gene disruption enables functional interrogation of MYG1 in a cancer-relevant background.
The KYSE-150 host cell line originates from a poorly differentiated esophageal squamous cell carcinoma resected from a Japanese patient. As an established esophageal epithelial model, it retains hallmark cancerous features such as dysregulated cell cycle control and survival signaling, widely used for studying oncogenic mechanisms and therapeutic responses. The MYG1 knockout in this background enables dissection of mitochondrial protein functions specifically in esophageal cancer, providing insights into disease-relevant pathways.
MYG1 encodes a putative mitochondrial protein with suggested roles in cell proliferation and stress response, yet its molecular partners and regulatory mechanisms remain unknown. The protein is thought to influence mitochondrial homeostasis and cell cycle progression, potentially impacting metabolic adaptation and proliferation control. Because upstream regulators, downstream targets, and interacting factors are not characterized, this knockout model offers a valuable tool for unbiased discovery, enabling the identification of novel MYG1-associated pathways in cancer cells.
Ablating MYG1 function in KYSE-150 cells allows direct assessment of its contribution to esophageal carcinoma phenotypes, including growth, apoptosis resistance, and metabolic reprogramming. Comparative studies between knockout and parental populations can reveal dependencies on mitochondrial integrity, informing how MYG1 loss alters tumorigenicity and drug susceptibility. The model thus facilitates exploration of mitochondrial vulnerabilities in squamous cell carcinoma, potentially uncovering actionable targets for therapeutic intervention.
Typical applications include cell proliferation, colony formation, migration, and apoptosis assays to assess phenotypic consequences. Mitochondrial function assays such as Seahorse flux analysis can quantify metabolic changes, while RNA-seq, RT-qPCR, and western blotting enable molecular profiling. Drug sensitivity studies can identify synthetic lethal interactions or resistance mechanisms. This polyclonal knockout pool supports both mechanistic investigations and high-throughput screens in an esophageal cancer model. For further technical details, please contact Ascent Research.
